Clinical Trial

MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity

Study acronym: MOTS-MET
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This Phase 2a study evaluates whether 12 weeks of treatment with investigational MOTS-c improves insulin sensitivity compared with placebo in adults with prediabetes and overweight/obesity. Participants are randomized 1:1 to MOTS-c or placebo, receive standardized lifestyle counseling, and are followed for safety through Week 16.
Trial Details
NCT Number NCT07505745
Lead Sponsor Hudson Biotech
Conditions Prediabetes, Insulin Resistance, Overweight/Obesity
Enrollment 120 participants
Start Date 2026-02-02
Primary Completion 2027-02-14 (estimated)
Study Completion 2028-05-17 (estimated)
Updated on ClinicalTrials.gov 2026-04-01